To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy
Phase 3
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-jRCT2080220244
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
Inclusion Criteria:
- Diagnosis of type 2 diabetes and treated with a stable dose of sulfonylurea
- Patients on diet and exercise who have not reached target blood glucose levels
- Outpatients
Exclusion Criteria
- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- Significant cardiovascular complications as defined by the protocol
- Significant diabetic complications as defined by the protocol
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method